Download PDF
Arthritis und Rheuma 2024; 44(03): 174-180
DOI: 10.1055/a-2271-0147
Schwerpunkt

Impfen in schwierigen Situationen

Michael Borte
1   Klinik für Kinder- und Jugendmedizin und ImmunDefektCentrum Leipzig (IDCL), Klinikum St. Georg gGmbH Leipzig, Leipzig
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

ZUSAMMENFASSUNG

Fehlgeleitete Immunreaktionen bei Patienten mit Autoimmunerkrankungen triggern wesentlich deren intrinsische Infektionsanfälligkeit. Diese wird noch verstärkt durch verschiedene Medikamente und immunsuppressive Therapien. Viele dieser Infektionen sind jedoch impfpräventabel und ein umfassender Impfschutz unserer Patienten mit rheumatischen oder Autoimmunerkrankungen ist erwünscht. Der behandelnde Arzt muss seine Entscheidungen im Spannungsfeld zwischen Infektionsrisiko, Impfrisiko und Impferfolg treffen. Die Behandlung mit Immunsuppressiva gehört zu den am häufigsten genannten Gründen für Indikationsimpfungen in den jährlich aktualisierten Empfehlungen der Ständigen Impfkommission am Robert Koch-Institut. Viele Fragen bleiben aber offen, da Krankheitsbilder und deren Behandlung durch Immunsuppressiva sehr unterschiedlich sind.

Schlüsselwörter

Autoimmunerkrankungen - immunsuppressive Therapie - impfpräventable Erkrankungen - Totimpfungen - Lebendimpfungen


Publication History

Article published online:
05 June 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Bach J. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002; 347 (12) 911-920
    CrossrefPubMedGoogle Scholar
  • 2 Empfehlungen der Ständigen Impfkommission beim Robert Koch-Institut 2023. Epidemiologisches Bulletin 4/2023 vom 26. Januar 2023
  • 3 Wagner N, Assmus F, Arendt G. et al Impfen bei Immundefizienz; Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen. Impfen bei Autoimmunkrankheiten, bei anderen chronisch-entzündlichen Erkrankungen und unter immunmodulatorischer Therapie. Bundesgesundheitsblatt – Gesundheitsforschung – Gesundheitsschutz 2019; 62 (04) 494
    CrossrefPubMedGoogle Scholar
  • 4 Haas J, Braun S, Wutzler P. Burden of influenza in Germany: a retrospective claims database analysis for the influenza season 2012/2013. Eur J Health Econ 2016; 17 (06) 669-679
    CrossrefPubMedGoogle Scholar
  • 5 Luque Ramos A, Hoffmann F, Callhoff J. et al Influenza and pneumococcal vaccination in patients with rheumatoid arthritis in comparison with age- and sex-matched controls: results of a claims data analysis. Rheumatol Int 2016; 36 (09) 1255-1263
    CrossrefPubMedGoogle Scholar
  • 6 Robert-Koch Institut Impfquoten bei der Schuleingangsuntersuchung in Deutschland 2017. Epidemiologisches Bulletin 2019 May 2. 147-153
    Google Scholar
  • 7 Poethko-Muller C, Kuhnert R, Gillesberg Lassen S, Siedler A. Vaccination coverage of children and adolescents in Germany: New data from KiGGS Wave 2 and trends from the KiGGS study. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2019; 62 (04) 410-421
    PubMedGoogle Scholar
  • 8 Niehues T, Bogdan C, Hecht J. et al Impfen bei Immundefizienz. Bundesgesundheitsblatt – Gesundheitsforschung – Gesundheitsschutz 2017; 60 (06) 674-684
    CrossrefPubMedGoogle Scholar
  • 9 Ehl S, Bogdan C, Niehues T. et al Impfen bei Immundefizienz: Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen. (II) Impfen bei 1. Primären Immundefekterkrankungen und 2. HIV-Infektion. Bundesgesundheitsblatt – Gesundheitsforschung – Gesundheitsschutz 2018; 61: 1034-1051
    CrossrefPubMedGoogle Scholar
  • 10 Wilking H, Buda S, von der Lippe E. et al Mortality of 2009 pandemic influenza A(H1N1) in Germany. Euro Surveill 2010; 15 (49) DOI: 10.2807/ese.15.49.19741-en.
    CrossrefPubMedGoogle Scholar
  • 11 Campbell CN, Mytton OT, McLean EM. et al Hospitalization in two waves of pandemic influenza A(H1N1) in England. Epidemiol Infect 2011; 139 (10) 1560-1569
    CrossrefPubMedGoogle Scholar
  • 12 van Hoek AJ, Andrews N, Waight PA. et al The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect 2012; 65 (01) 17-24
    CrossrefPubMedGoogle Scholar
  • 13 Schröder C, Enders D, Schink T, Riedel O. Incidence of herpes zoster amongst adults varies by severity of immunosuppression. J Infect 2017; 75 (03) 207-215
    CrossrefPubMedGoogle Scholar
  • 14 Beukelman T, Xie F, Baddley JW. et al The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis. Arthritis Res Ther 2016; 18 (01) 210-218
    CrossrefPubMedGoogle Scholar
  • 15 Hyams J, Crandall W, Kugathasan S. et al Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children. Gastroenterology 2007; 132 (03) 863-866
    CrossrefPubMedGoogle Scholar
  • 16 Nimmrich S, Horneff G. Incidence of herpes zoster infections in juvenile idiopathic arthritis patients. Rheumatol Int 2015; 35 (03) 465-470
    CrossrefPubMedGoogle Scholar
  • 17 Oikonen M, Laaksonen M, Aalto V. et al Temporal relationship between environmental influenza A and Epstein-Barr viral infections and high multiple sclerosis relapse occurrence. Mult Scler 2011; 17 (06) 672-680
    CrossrefPubMedGoogle Scholar
  • 18 Bengtsson C, Kapetanovic MC, Kallberg H. et al Common vaccinations among adults do not increase the risk of developing rheumatoid arthritis: results from the Swedish EIRA study. Ann Rheum Dis 2010; 69 (10) 1831-1833
    CrossrefPubMedGoogle Scholar
  • 19 Confavreux C, Suissa S, Saddier P. et al Vaccines in Multiple Sclerosis Study Group. Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. N Engl J Med 2001; 344 (05) 319-326
    CrossrefPubMedGoogle Scholar
  • 20 Croce E, Hatz C, Jonker EF. et al Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation – A systematic review of randomized trials, observational studies and case reports. Vaccine 2017; 35 (09) 1216-1226
    CrossrefPubMedGoogle Scholar
  • 21 Beck CR, McKenzie BC, Hashim AB, Harris RC. University of Nottingham Influenza and the ImmunoCompromised (UNIIC) Study Group, Nguyen-Van-Tam JS. Influenza vaccination for immunocompromised patients: systematic review and meta-analysis by etiology. J Infect Dis 2012; 206 (08) 1250-1259
    CrossrefPubMedGoogle Scholar
  • 22 Beck CR, McKenzie BC, Hashim AB. et al Influenza vaccination for immunocompromised patients: systematic review and meta-analysis from a public health policy perspective. PLoS One 2011; 06 (12) e29249
    CrossrefPubMedGoogle Scholar
  • 23 Westra J, van Assen S, Wilting KR. et al Rituximab impairs immunoglobulin (Ig)M and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients. Clin Exp Immunol 2014; 178 (01) 40-47
    CrossrefPubMedGoogle Scholar
  • 24 Ladhani SN, Andrews N, Parikh SR. et al Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in England. N Engl J Med 2020; 382 (04) 309-317
    CrossrefPubMedGoogle Scholar
  • 25 Bonten MJ, Huijts SM, Bolkenbaas M. et al Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015; 372 (12) 1114-1125
    CrossrefPubMedGoogle Scholar
  • 26 Rose MA, Gruendler M, Schubert R. et al Safety and immunogenicity of sequential pneumococcal immunization in preschool asthmatics. Vaccine 2009; 27 (38) 5259-5264
    CrossrefPubMedGoogle Scholar
  • 27 Folaranmi TA, Kretz CB, Kamiya H. et al Increased Risk for Meningococcal Disease Among Men Who Have Sex With Men in the United States, 2012–2015. Clin Infect Dis 2017; 65 (05) 756-763
    CrossrefPubMedGoogle Scholar
  • 28 Borja-Tabora CF, Montalban C, Memish ZA. et al Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial. BMC Infect Dis 2015; 15: 409-y
    CrossrefPubMedGoogle Scholar
  • 29 Flacco ME, Manzoli L, Rosso A. et al Immunogenicity and safety of the multicomponent meningococcal B vaccine (4CMenB) in children and adolescents: a systematic review and meta-analysis. Lancet Infect Dis 2018; 18 (04) 461-472
    CrossrefPubMedGoogle Scholar
  • 30 Shah RA, Limmer AL, Nwannunu CE. et al Shingrix for Herpes Zoster: A Review. Skin Therapy Lett 2019; 24 (04) 5-7
    PubMedGoogle Scholar
  • 31 Hertzell KB, Pauksens K, Rombo L. et al Tick-borne encephalitis (TBE) vaccine to medically immunosuppressed patients with rheumatoid arthritis: A prospective, open-label, multi-centre study. Vaccine 2016; 34 (05) 650-655
    CrossrefPubMedGoogle Scholar
  • 32 Laws HJ, Baumann U, Bogdan C. et al Impfen bei Immundefizienz: Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen. (III) Impfen bei hämatologischen und onkologischen Erkrankungen (antineoplastische Therapie, Stammzelltransplantation), Organtransplantation und Asplenie. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2020; 63 (05) 588-644
    CrossrefPubMedGoogle Scholar
  • 33 Kubiet MA, Gonzalez-Rothi RJ, Cottey R, Bender BS. Serum antibody response to Influenza vaccine in pulmonary patients receiving corticosteroids. Chest 1996; 110: 367-370
    CrossrefPubMedGoogle Scholar
  • 34 Dubesinghe S, Bechman K, Rutherford AI. et al A Systematic Review and Metaanalysis of Antirheumatic Drugs and Vaccine Immunogenicity in Rheumatoid Arthritis. J Rheumatol 2018; 45: 733-744
    CrossrefPubMedGoogle Scholar
  • 35 Coulson E, Saravanan V, Hamilton J. et al Pneumococcal antibody levels after pneumovax in patients with rheumatoid arthritis on methotrexate. Ann Rheum Dis 2011; 70: 1289-1291
    CrossrefPubMedGoogle Scholar
  • 36 Park JK, Lee MA, Lee EY. et al Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis 2017; 76: 1559-1565
    CrossrefPubMedGoogle Scholar
  • 37 Park JK, Lee YJ, Shin K. et al Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis 2018; 77: 898-904
    PubMedGoogle Scholar
  • 38 Bingham CO 3 rd Rizzo W, Kivitz A. et al Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA). Ann Rheum Dis 2015; 74: 818-822
    CrossrefPubMedGoogle Scholar
  • 39 Mori S, Ueki Y, Hirakata N. et al Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis. Ann Rheum Dis 2012; 71: 2006-2010
    CrossrefPubMedGoogle Scholar
  • 40 Ribeiro AC, Laurindo IM, Guedes LK. et al Abatacept and reduced immune response to pandemic 2009 influenza A/H1N1 vaccination in patients with rheumatoid arthritis. Arthritis Care Res 2013; 65: 476-480
    CrossrefPubMedGoogle Scholar
  • 41 Arad U, Tzadok S, Amir S. et al The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. Vaccine 2011; 29: 1643-1648
    CrossrefPubMedGoogle Scholar
  • 42 Bar-Or A, Calkwood JC, Chognot C. et al Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study. Neurology 2020; 95 (14) e1999-e2008
    CrossrefPubMedGoogle Scholar
  • 43 Winthrop KL, Silverfield J, Racewicz A. et al The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. Ann Rheum Dis 2016; 75: 687-695
    CrossrefPubMedGoogle Scholar
  • 44 Richi P, Martín MD, de Ory F. et al Secukinumab does not impair the immunogenic response to the influenza vaccine in patients. RMD Open 2019 DOI: 10.1136/rmdopen-2019-001018
    CrossrefPubMedGoogle Scholar